Nicholas: A challenging phase - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Nicholas: A challenging phase

Mar 31, 2004

Nicholas Piramal (NPIL) is one of the leading pharma companies in India with a strong presence in branded formulations markets, focusing on lifestyle drugs. It is one of the companies, which has chosen an inorganic growth path. Its acquisitions include pharmaceuticals business of ICI India, Global Bulk Drugs and Fine Chemicals, Sarabhai Pharmaceuticals. The company recently merged itself with Canere Actives and Fine chemicals.

Business Segment % Sales
Domestic 90.9
Branded Formulations 72.4
Generics 4.5
API 1.2
Vitamins & Fine Chemicals 6.1
Diagnostics 6.7
Exports 8.7
Branded Formulations 2.4
API 5.4
Vitamins & Fine Chemicals 0.9

On the exports front, the company is not as aggressive as other players. Unlike other companies, NPIL is entering into exports markets as a contract manufacturer to foreign companies. Given the natural advantage of Indian companies on costs front, contract-manufacturing offer promising growth potential. NPIL has recently signed a 5-year contract with AMO Corporation of USA for manufacturing of eye-care products to be sold in US, Europe and the Japanese markets. In this regard, the declared strategy of the company is to partner with the innovator company from the pre-launch stage to patent expiry. They will be involved with in the project throughout the value chain through contract research and contract manufacturing. According to the company, there are several other such deals in the pipeline.

In the domestic market, the company has focused on branded formulations as the major business segment. Although NPIL is a strong player in the respiratory segment, its major thrust area for driving growth is life style segments like CVS (cardiovascular), CNS (Central Nervous System) and anti-diabetics (31% of revenues are derived from the lifestyle segment and the growth in this segment has been above the normal industry growth rates). Focus on lifestyle segment means above average growth rate for the company in future.

The following table gives the revenue breakup from various segments and their growth rates in the first nine months of FY04.

Therapeutic Area % Sales Growth
Respiratory 22.9 19.1
Anti-Infective 10.3 -2.5
CVS 9.5 23.9
CNS 9.4 13.4
Nutritional 7.6 7.4
Biotek 7.3 -4.8
Anti-Diabetic 4.7 34.2
Gastro-Intestinal 4.4 -2.5
Dermatology 4.5 33.7
NSAIDs 2.8 17.9
Others 16.4 19.2

Year 2005 is likely to bring new challenges and opportunities for domestic pharma majors. Although Nicholas Piramal has been one of the leading players in the domestic market, this new environment can bring about serious problems for the company considering the fact that there does not seem to be any clear cut R&D policy that company has adopted.

At Rs 725, NPIL is trading at a P/E multiple of 19x FY04 our earnings estimates. Although the company has seen strong growth in revenues in recent times through acquisitions, lack of clear management direction post 2005 is the area of concern.


Equitymaster requests your view! Post a comment on "Nicholas: A challenging phase". Click here!

  

More Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 18, 2020 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS